1.63Open1.30Pre Close8 Volume62 Open Interest45.00Strike Price861.00Turnover83.27%IV6.05%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry1.10Extrinsic Value100Contract SizeAmericanOptions Type0.3583Delta0.1022Gamma51.14Leverage Ratio-0.1970Theta0.0015Rho18.32Eff Leverage0.0164Vega
Janux Therapeutics Stock Discussion
$Merck & Co(MRK.US)$ already has an active partnership with $Janux Therapeutics(JANX.US)$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF(XBI.US)$ in which $Merck & Co(MRK.US)$ already has a seat at the table.
$Merck & Co(MRK.US)$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US)$
$Vaxcyte(PCVX.US)$
$Legend Biotech(LEGN.US)$
$Janux Therapeutics(JANX.US)$
$Aerovate(AVTE.US)$
$Rhythm Pharmaceuticals(RYTM.US)$
$Evolent Health(EVH.US)$
$NewAmsterdam Pharma(NAMS.US)$
$RxSight(RXST.US)$
$TYRA BIOSCIENCES, INC.(TYRA.US)$
$Edgewise Therapeutics(EWTX.US)$
$4D Molecular Therapeutics(FDMT.US)$
$Biogen(BIIB.US)$
$PepGen(PEPG.US)$